Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivationviaarginine deiminase
Open Access
- 27 December 2006
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 120 (4), 897-905
- https://doi.org/10.1002/ijc.22322
Abstract
Recently, pegylated arginine deiminase (ADI; EC 3.5.3.6) has been used to treat the patients with hepatocellular carcinoma or melanoma, in which the level of argininosuccinate synthetase (ASS) activity is low or undetectable. The efficacy of its antitumor activity largely depends on the level of intracellular ASS, which enables tumor cells to recycle citrulline to arginine. Thus, we examined the expression levels of ASS in various cancer cells and found that it is low in renal cell carcinoma (RCC) cells, rendering the cells highly sensitive to arginine deprivation by ADI treatment. Immunohistochemical analysis revealed that in biopsy specimens from RCC patients (n = 98), the expression of ASS is highly demonstrated in the epithelium of normal proximal tubule but not seen in tumor cells. Furthermore, RCC cells treated with ADI showed remarkable growth retardation in a dose dependent manner. ADI also exerted in vivo antiproliferative effect on the allografted renal cell carcinoma (RENCA) tumor cells and prolonged the survival of tumor‐bearing mice. Histological examination of the tumors revealed that tumor angiogenesis and vascular endothelial growth factor (VEGF) expression were significantly diminished by ADI administration. Therefore, these findings suggest that arginine deprivation by ADI could provide a beneficial strategy for the treatment of RCC in ways of inhibitions of arginine availability and neovascularization.Keywords
Funding Information
- Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (A050252)
This publication has 33 references indexed in Scilit:
- Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminaseCancer Letters, 2006
- Pegylated Arginine Deiminase Treatment of Patients With Metastatic Melanoma: Results From Phase I and II StudiesJournal of Clinical Oncology, 2005
- Arginine deiminase enhances dexamethasone‐induced cytotoxicity in human T‐lymphoblastic leukemia CCRF‐CEM cellsInternational Journal of Cancer, 2004
- Pegylated Arginine Deiminase Treatment of Patients With Unresectable Hepatocellular Carcinoma: Results From Phase I/II StudiesJournal of Clinical Oncology, 2004
- Incidence and distribution of argininosuccinate synthetase deficiency in human cancersCancer, 2004
- Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: Potentiation by irradiationInternational Journal of Cancer, 2003
- Expression of vascular endothelial growth factor in renal cell carcinoma is correlated with cancer advancementJournal of Clinical Laboratory Analysis, 2003
- High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitroMelanoma Research, 1992
- Multiple Comparisons Using Rank SumsTechnometrics, 1964